TriangleHEALTH PROFESSIONAL · SOURCE READING
Classical Hodgkin lymphoma, low-risk disease
Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 16, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Table 7 summarizes the results of treatment approaches used for pediatric patients with low-risk Hodgkin lymphoma.
Source links and citations
| Chemotherapy (No. of Cycles)a | Radiation (Gy) | Stage | No. of Patients | Event-Free Survival Rate (No. of Years of Follow-up) | Survival Rate (No. of Years of Follow-up) |
|---|---|---|---|---|---|
| CS = clinical stage; IFRT = involved-field radiation therapy; N/A = not applicable; No. = number. | |||||
| aFor more information about the chemotherapy regimens, see Table 6. | |||||
| bIncluded patients with nodular lymphocyte-predominant Hodgkin lymphoma. | |||||
| OEPA (2) [24] | IFRT (20–35) | I, IIA | 281 | 94% (5) | N/A |
| None | 113 | 97% (5) | |||
| ABVD [78] | IFRT (21–35) | I–IV | 209 | 85% (5) | 97% (5) |
| ABVE (2-4)b [66] | IFRT (25.5) | IA, IIA, IIIA1, without bulky disease | 51 | 91% (6) | 98% (6) |
| AV-PC [44] | None | IA, IIA, without bulky disease | 278 | 79.9% (4) | 99.6% (4) |
| Response-based IFRT (21) | |||||
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice